E75+GM−CSF vaccination was applied in 16 patients with HER2/neu-expressing primary breast cancer, while thirteen of the 16 patients (81.3%) had at least one HER2/neu+CTC (mean: 2.1 ± 0.1 CTC/20 mL) in the peripheral blood. This evidence concerns the gene ERBB2 and breast carcinoma.